SGLT2 inhibitors: Molecular design and potential differences in effect

Kidney International

Volumn 79, Issue SUPPL. 120, 2011, Pages

  Isaji, Masayuki ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

dapagliflozin; diabetes; glucosuria; insulin resistance; phlorizin; SGLT2

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; 4' DEHYDROXYPHLORIZIN DERIVATIVE; ANTIDIABETIC AGENT; ASP 1941; AVE 2268; BI 10773; BI 44847; BI 448747; CANAGLIFLOZIN; DAPAGLIFLOZIN; LX 4211; PHLORIZIN; R 7201; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TS 033; TS 071; UNCLASSIFIED DRUG; WAY 123783; YM 543;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GENITAL TRACT INFECTION; GLUCOSE ABSORPTION; HUMAN; HYPERGLYCEMIA; IC 50; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; URINARY TRACT INFECTION;

EID: 79952229724     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.511     Document Type: Review

References (52)

1. Brunton SA. The changing shape of type 2 diabetes. Medscape J Med 2008; 10: 143.
2. Hays NP, Galassetti PR, Coker RH. Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions. Pharmacol Ther 2008; 118: 181-191.
3. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721. (Pubitemid 44025023)
4. Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med 2009; 150: 803-808.
5. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008; 14: 782-790.
6. Wright EM, Loo DD, Hirayama BA et al. Surprising versatility of Na+-glucose cotransporters: SLC5. Physiology (Bethesda) 2004; 19: 370-376. (Pubitemid 39636085)
7. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009; 53: 875-883.
8. Kanai Y, Lee WS, You G et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397-404.
9. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007; 8: 285-292. (Pubitemid 46557988)
10. Tazawa S, Yamato T, Fujikura H et al. SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci 2005; 76: 1039-1050. (Pubitemid 39643403)
11. Brodehl J, Oemar BS, Hoyer PF. Renal glucosuria. Pediatr Nephrol 1987; 1: 502-508. (Pubitemid 18016652)
12. van den Heuvel LP, Assink K, Willemsen M et al. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002; 111: 544-547. (Pubitemid 36075086)
13. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279-1284. (Pubitemid 351977622)
14. Kipnes M. Dapagliflozin: an emerging treatment option in type 2 diabetes. Expert Opin Investig Drugs 2009; 18: 327-334.
15. Handlon AL. Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents. Expert Opin Ther Pat 2005; 15: 1531-1540. (Pubitemid 41671615)
16. Ehrenkranz JR, Lewis NG, Kahn CR et al. Phlorizin: a review. Diabetes Metab Res Rev 2005; 21: 31-38.
17. Tsujihara K, Hongu M, Saito K et al. Na(+)-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 40-dehydroxyphlorizin derivatives substituted on the B ring. J Med Chem 1999; 42: 5311-5324. (Pubitemid 30036767)
18. Katsuno K, Fujimori Y, Takemura Y et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320: 323-330. (Pubitemid 46025747)
19. Fujimori Y, Katsuno K, Nakashima I et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-276.
20. Zhang X, Urbanski M, Patel M et al. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2. Bioorg Med Chem Lett 2006; 16: 1696-1701. (Pubitemid 43197548)
21. Link JT, Sorensen BK. A method for preparing C-glycosides related to phlorizin. Tetrahedron Lett 2000; 41: 9213-9217.
22. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149. (Pubitemid 351480378)
23. Rossetti L, Smith D, Shulman GI et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510-1515. (Pubitemid 17099657)
24. Seidner G, Alvarez MG, Yeh JI et al. GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 1998; 18: 188-191. (Pubitemid 28082472)
25. Oku A, Ueta K, Arakawa K et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794-1800. (Pubitemid 29415199)
26. Oku A, Ueta K, Arakawa K et al. Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats. Jpn J Pharmacol 2000; 84: 351-354. (Pubitemid 32000463)
27. Oku A, Ueta K, Nawano M et al. Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol 2000; 391: 183-192. (Pubitemid 30138095)
28. Nawano M, Oku A, Ueta K et al. Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats. Am J Physiol Endocrinol Metab 2000; 278: E535-E543. (Pubitemid 30149399)
29. Fujimoto Y, Torres TP, Donahue EP et al. Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats. Diabetes 2006; 55: 2479-2490. (Pubitemid 44871148)
30. Nunoi K, Yasuda K, Adachi T et al. Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol 2002; 29: 386-390. (Pubitemid 34535357)
31. Arakawa K, Ishihara T, Oku A et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001; 132: 578-586. (Pubitemid 32142370)
32. Ueta K, Ishihara T, Matsumoto Y et al. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 2005; 76: 2655-2668. (Pubitemid 40404055)
33. Hanefeld M, Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 2008; 6: 153-163. (Pubitemid 351372584)
34. Debnam ES, Smith MW, Sharp PA et al. The effects of streptozotocin diabetes on sodium-glucose transporter (SGLT1) expression and function in rat jejunal and ileal villus-attached enterocytes. Pflugers Arch 1995; 430: 151-159.
35. Turk E, Zabel B, Mundlos S et al. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature 1991; 350: 354-356. (Pubitemid 21912230)
36. Zhou L, Cryan EV, D'Andrea MR et al. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem 2003; 90: 339-346. (Pubitemid 37222202)
37. Kees KL, Fitzgerald Jr JJ, Steiner KE et al. New potent antihyperglycemic agents in db/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl) (trifluoromethyl)pyrazoles and-pyrazolones. J Med Chem 1996; 39: 3920-3928. (Pubitemid 26327429)
38. Ohsumi K, Matsueda H, Hatanaka T et al. Pyrazole-O-glucosides as novel Na(+)-glucose cotransporter (SGLT) inhibitors. Bioorg Med Chem Lett 2003; 13: 2269-2272. (Pubitemid 36724963)
39. Fujimori Y, Katsuno K, Ojima K et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009; 609: 148-154.
40. Hussey EK, Dobbins RI, Stolz RR et al. A double-blind randomized repeat dose to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy overweight and obese subjects [0491-P]. Diabetes 2007; 56: A491.
41. Stonehouse AH, Holcombe JH, Kendall DM. Management of Type 2 diabetes: the role of incretin mimetics. Expert Opin Pharmacother 2006; 7: 2095-2105.
42. Kapur A, O'Connor-Semmes R, Hussey E et al. First human dose-escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus (T2DM) [509-P]. Diabetes 2009; 58: A136.
43. Komoroski B, Vachharajani N, Feng Y et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519.
44. Dobbins R, Kapur A, Kapitza C et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2) reduces serum glucose in type 2 diabetes mellitus (T2DM) patients [573-P]. Diabetes 2009; 58: A154.
45. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729.
46. List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
47. Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009; 25: 671-681.
48. Bickel M, Brummerhop H, Frick W et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung 2008; 58: 574-580.
49. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol 1998; 274: R263-R279.
50. Thomson SC, Blantz RC. Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis. J Am Soc Nephrol 2008; 19: 2272-2275.
51. Leiter LA, Ceriello A, Davidson JA et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27(Suppl B): S42-S46.
52. Herman MA, Kahn BB. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J Clin Invest 2006; 116: 1767-1775. (Pubitemid 44033296)